Clévio Nóbrega, CBMR researcher, has recently established a partnership with BrainVectis, a biotechnology company based in Paris, to test a genetically based therapy for neurodegenerative diseases.

The Molecular Neuroscience and Therapy Lab will, over the next six months, carry out, in cellular models, additional tests about the mechanism of action of the therapy.

If the tests are successful, the company, whose main objective is to stop the progression of neurodegenerative diseases, will continue to focus on the investigation of Clévio Nóbrega (who was, in 2017, distinguished with the Award of Young Scientist of the Year), moving towards experiments on animal models.

Know more about the research here.